当前位置： SCI文献检索 > Multiple Sclerosis and Related Disorders期刊下所有文献 > Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.

Abstract：

BACKGROUND:MS imposes a significant burden on patients, caregivers, employers, and the healthcare system. OBJECTIVE:To comprehensively evaluate the US MS burden using nationally representative data from the Medical Expenditure Panel Survey. METHODS:We identified non-institutionalized patients aged ≥18 with MS (ICD-9 code 340) from 1998 to 2009 and compared them to individuals without an MS diagnosis (non-MS) during the interview year. The cohorts were compared using multivariate regression on direct costs, indirect costs (measured in terms of employment status, annual wages, and workdays missed), and health-related quality of life (HRQoL; measured using Short Form 12, SF-6 Dimensions, and quality-adjusted life years [QALYs]). RESULTS:MS prevalence was 572,312 (95% CI: 397,004, 747,619). Annual direct costs were $24,327 higher for the MS population (n=526) vs. the non-MS population (n=270,345) (95% CI: $22,320, $26,333). MS patients had an adjusted 3.3-fold (95% CI: 2.4, 4.5) increase in the odds of not being employed vs. non-MS individuals and a 4.4-fold higher adjusted number of days in bed (95% CI 2.97, 6.45). On average, MS patients lost 10.04 QALYs vs. non-MS cohort. CONCLUSIONS:MS was associated with higher healthcare costs across all components, reduced productivity due to unemployment and days spent in bed, and lower HRQoL.

journal_name

Mult Scler Relat Disord

journal_title

Multiple sclerosis and related disorders

authors

Campbell JD,Ghushchyan V,Brett McQueen R,Cahoon-Metzger S,Livingston T,Vollmer T,Corboy J,Miravalle A,Schreiner T,Porter V,Nair K

doi

10.1016/j.msard.2013.09.004

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

227-36

issue

2

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(13)00112-0

journal_volume

3

pub_type

杂志文章

相关文献

Multiple Sclerosis and Related Disorders文献大全
  • Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis.

    abstract：PURPOSE:To what extent depression may negatively impact successful aging with multiple sclerosis (MS) is not known. We examined the impact of depression/depressive symptoms on lifestyle choices (diet, exercise, smoking and alcohol), participation and health-related quality of life (HRQoL) among older people living with...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.msard.2019.101919

    authors： Ploughman M,Wallack EM,Chatterjee T,Kirkland MC,Curtis ME,Health Lifestyle and Aging with MS Consortium.

    更新日期：2020-05-01 00:00:00

  • Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries.

    abstract：BACKGROUND:We characterize the variations in availability and affordability of NMO diagnostic testing and treatment by geographic region and country-level income group. METHODS:A structured survey was distributed in English, French, and Spanish in late 2018 to neurologists and other physicians who encounter NMO patien...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.05.013

    authors： Holroyd K,Vogel A,Lynch K,Gazdag B,Voghel M,Alakel N,Patenaude BN,Chiong-Rivero H,Mateen FJ

    更新日期：2019-08-01 00:00:00

  • Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.

    abstract：:Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.04.005

    authors： Barroso B,Miquel M,Marasescu R,Demasles S,Krim E,Bonnan M

    更新日期：2015-07-01 00:00:00

  • Olfactory dysfunction in multiple sclerosis.

    abstract：BACKGROUND:Multiple sclerosis (MS) is a common chronic neurological disease that causes disability. MS can have various clinical manifestations, one of which is olfactory dysfunction. In clinical practice, olfactory disturbances are usually underdiagnosed. The aim of our study is to assess olfactory function and its re...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2018.02.032

    authors： Atalar AÇ,Erdal Y,Tekin B,Yıldız M,Akdoğan Ö,Emre U

    更新日期：2018-04-01 00:00:00

  • Real-time assessment of daytime sleepiness in drivers with multiple sclerosis.

    abstract：BACKGROUND:Daytime sleepiness is a common symptom of multiple sclerosis (MS) that may jeopardize safe driving. Our aim was to compare daytime sleepiness, recorded in real-time through eyelid tracking, in a simulated drive between individuals with MS (iwMS) and healthy controls. METHODS:Fifteen iwMS (age = median (Q1 -...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102607

    authors： Devos H,Alissa N,Lynch S,Sadeghi M,Akinwuntan AE,Siengsukon C

    更新日期：2020-10-31 00:00:00

  • Clinical decision-making in multiple sclerosis: Challenges reported internationally with emerging treatment complexity.

    abstract：INTRODUCTION:The introduction of several new disease-modifying therapies (DMTs) to the field of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a comprehensive understanding of the implications of each new treatment option in order to select the treatment that best suits their patient. An i...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.05.008

    authors： Ng P,Murray S,Hayes SM

    更新日期：2015-07-01 00:00:00

  • Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study.

    abstract：BACKGROUND:Growing evidence supports the efficacy of restorative cognitive training in people with multiple sclerosis (PwMS), but the effects vary across individuals. Differences in treatment efficacy may be related to baseline individual differences. We investigated clinical characteristics and MRI variables to predic...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.06.026

    authors： Fuchs TA,Ziccardi S,Dwyer MG,Charvet LE,Bartnik A,Campbell R,Escobar J,Hojnacki D,Kolb C,Oship D,Pol J,Shaw MT,Wojcik C,Yasin F,Weinstock-Guttman B,Zivadinov R,Benedict RHB

    更新日期：2019-09-01 00:00:00

  • Prevalence of multiple sclerosis in Health District III, Murcia, Spain.

    abstract：BACKGROUND:The prevalence of multiple sclerosis (MS) varies throughout the world, and available epidemiological data suggest a progressively increasing prevalence of MS in Spain. The objective of this study was to calculate MS prevalence in Health District III of the autonomous community of Murcia in Spain. METHODS:Th...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2016.06.003

    authors： Candeliere-Merlicco A,Valero-Delgado F,Martínez-Vidal S,Lastres-Arias Mdel C,Aparicio-Castro E,Toledo-Romero F,Villaverde-González R

    更新日期：2016-09-01 00:00:00

  • Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases.

    abstract：BACKGROUND:Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102243

    authors： Nali LH,Olival GS,Sousa FTG,de Oliveira ACS,Montenegro H,da Silva IT,Dias-Neto E,Naya H,Spangenberg L,Penalva-de-Oliveira AC,Romano CM

    更新日期：2020-09-01 00:00:00

  • Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.

    abstract：BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102208

    authors： Edgar Patricio CD,Eleanor THG,Francisco José CZ,Gabriela ACM,Hyland AO,Fernando GL,María TA,Beatriz N,Marcos SD,Alfredo GPW

    更新日期：2020-09-01 00:00:00

  • Intravenous immunoglobulins for the prevention of postpartum relapses in multiple sclerosis.

    abstract：OBJECTIVES:To evaluate the effect of intravenous immunoglobulins (IVIG) on prevention of postpartum relapses in women with relapsing-remitting multiple sclerosis (RRMS). METHODS:This was a retrospective study performed in Ljubljana, Slovenia where the practice for all pregnant women with RRMS is to receive IVIG after ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.msard.2019.101519

    authors： Horvat Ledinek A,Brecl Jakob G,Jerše J,Ruška B,Pavičić T,Gabelić T,Barun B,Adamec I,Rot U,Šega Jazbec S,Krbot Skorić M,Habek M

    更新日期：2020-02-01 00:00:00

  • Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease.

    abstract：INTRODUCTION:Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have recently been associated with epilepsy with FLAIR hyperintense cortical lesions on MRI. Association between anti-MOG antibodies and epilepsy without detectable structural brain lesion on MRI is unknown. CASE REPORT:A 48-year-old right-handed m...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2018.10.012

    authors： Katsuse K,Kurihara M,Sugiyama Y,Kodama S,Takahashi M,Momose T,Yumoto M,Kaneko K,Takahashi T,Kubota A,Hayashi T,Toda T

    更新日期：2019-01-01 00:00:00

  • Prognostic value of odor identification impairment in multiple sclerosis: 10-Years follow-up.

    abstract：BACKGROUND:Olfactory dysfunction has been linked to clinical severity variables in multiple MS populations. Though, its prognostic value is still unknown. OBJECTIVE:The aim of this study was to explore the long-term outcome associated with Brief-Smell Identification Test (B-SIT) performance in a cohort of MS patients....

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102486

    authors： da Silva AM,Torres C,Ferreira I,Moreira I,Samões R,Sousa AP,Santos E,Teixeira-Pinto A,Cavaco S

    更新日期：2020-11-01 00:00:00

  • Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

    abstract：BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) that preferentially targets the spinal cord and optic nerves. Increasing disability is accrued with each inflammatory attack. Disability has been shown to be an independent predictor of poor quality of...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.msard.2018.12.011

    authors： Mealy MA,Mossburg SE,Kim SH,Messina S,Borisow N,Lopez-Gonzalez R,Ospina JP,Scheel M,Yeshokumar AK,Awad A,Leite MI,Arango JJ,Paul F,Palace J,Kim HJ,Levy M

    更新日期：2019-02-01 00:00:00

  • Weight status and disability in multiple sclerosis: An examination of bi-directional associations over a 24-month period.

    abstract：BACKGROUND:Natural history studies have typically focused on non-modifiable factors as predictors of disability progression in multiple sclerosis (MS). Weight status has emerged as a correlate of disability status in cross-sectional studies of persons with MS and represents a possible modifiable predictor of disability...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2012.02.004

    authors： Pilutti LA,McAuley E,Motl RW

    更新日期：2012-07-01 00:00:00

  • Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.

    abstract：BACKGROUND:Natalizumab is a monoclonal antibody that significantly reduces the occurrence of relapses in relapse-remitting multiple sclerosis (RRMS) patients. Early papers on the clinical use of natalizumab in RRMS patients reported erythroblastemia as occasional and transient. OBJECTIVES:to determine the prevalence a...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2016.05.020

    authors： La Gioia S,Seghezzi M,Barcella V,Dominoni P,Mecca T,Frigeni B,Conti MZ,Vedovello M,Vidali M,Rottoli M,Buoro S

    更新日期：2016-07-01 00:00:00

  • Integration of the Extreme Gradient Boosting model with electronic health records to enable the early diagnosis of multiple sclerosis.

    abstract：BACKGROUND:Delayed multiple sclerosis (MS) diagnoses are not uncommon, an early diagnostic tool is urgently warranted. We aimed to develop an effective tool through electronic health records and machine learning techniques to early recognize MS patients from hospital visitors in China. METHODS:Two case sets were colle...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102632

    authors： Wang R,Luo W,Liu Z,Liu W,Liu C,Liu X,Zhu H,Li R,Song J,Hu X,Han S,Qiu W

    更新日期：2020-11-18 00:00:00

  • Hypocomplementemic urticarial vasculitis and multiple Sclerosis: A rare association or an atypical presentation?

    abstract：BACKGROUND:Multiple Sclerosis (MS) has been associated with several immune-mediated diseases but the mechanisms that explain such associations, as well as their implications in clinical practice and treatment are rarely discussed. CASE PRESENTATION:We report the case of a patient with a history of MS since she was 27 ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.02.020

    authors： Durães J,Gonçalo M,Sousa L,Macário MC

    更新日期：2019-05-01 00:00:00

  • To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.

    abstract：BACKGROUND:The frequency and long-term prognosis of relapsing multiple sclerosis (RMS) never receiving disease-modifying treatment (DMT) is unclear. METHODS:We included 1186 RMS patients with a mean of 17.4 years follow-up and divided them into patients treated with any DMT (DMT) and patients untreated by shared (USD)...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.101908

    authors： Bsteh G,Hegen H,Dosser C,Auer M,Berek K,Wurth S,Zinganell A,Di Pauli F,Deisenhammer F,Berger T

    更新日期：2019-12-23 00:00:00

  • Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.

    abstract：INTRODUCTION:Natalizumab break exposes multiple sclerosis (MS) patients to a high risk of disease reactivation or rebound, whose prevention and treatment constitute a clinical challenge. CASE PRESENTATION:We describe a dramatic case of MS rebound, characterized by the development of severe neurological and psychiatric...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2019.03.002

    authors： Federle L,Puthenparampil M,Stenta G,Paolo G,Francesco P

    更新日期：2019-05-01 00:00:00

  • Placebo controlled trials in neuromyelitis optica are needed and ethical.

    abstract：:Currently, there are no approved treatments for NMO. All therapeutic studies in NMO have been either small, retrospective case series or uncontrolled prospective studies. Such studies are susceptible to inherent biases. As a consequence, conclusions regarding efficacy and safety from these studies may be erroneous. Th...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2015.07.017

    authors： Cree BA

    更新日期：2015-11-01 00:00:00

  • Screening of dysphagia by DYMUS (Dysphagia in multiple sclerosis) and SWALQoL (Swallowing quality of life) surveys in patients with multiple sclerosis.

    abstract：BACKGROUND:Dysphagia is a life-threating symptom in patients with multiple sclerosis (MS) because aspiration pneumonia develops as a consequence of swallowing disorders. Dysphagia can be detected by using patient-reported outcome measures in order to prevent complications. OBJECTIVE:To identify the dysphagia prevalenc...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102397

    authors： Tahir E,Kavaz E,Kemal Ö,Şen S,Terzi M

    更新日期：2020-10-01 00:00:00

  • Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

    abstract：OBJECTIVE:Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. BACKGROUND:Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The en...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2013.05.003

    authors： Thaera GM,Wingerchuk DM,Carter JL

    更新日期：2014-01-01 00:00:00

  • Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.

    abstract：:Thrombotic microangiopathy (TMA) is a rare but increasingly recognized complication of interferon-beta therapy, which can be associated with serious sequelae. We report on a 53-year-old woman with a longstanding history of relapsing-remitting multiple sclerosis, who developed TMA after 15 years of high-dose treatment ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2016.09.002

    authors： Gerischer LM,Siebert E,Janke O,Jungehuelsing GJ,Ruprecht K

    更新日期：2016-11-01 00:00:00

  • Health-related quality of life in patients with longstanding 'benign multiple sclerosis'.

    abstract：BACKGROUND:We explored health-related quality of life (HRQoL) and psychosocial aspects in a cohort of patients with a history of longstanding benign MS (BMS). METHODS:Patients with BMS (EDSS≤3 after 20 years disease duration) were re-assessed 25-30 years post-MS symptom onset for: EDSS, HRQoL (MSQoL-54), depression (B...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2014.09.211

    authors： Bueno AM,Sayao AL,Yousefi M,Devonshire V,Traboulsee A,Tremlett H

    更新日期：2015-01-01 00:00:00

  • Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.

    abstract：BACKGROUND:Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease in the central nerve system, in which both innate and adaptive immune cells are involved. BBR3378, an aza-anthrapyrazole prevents experimental autoimmune encephalomyelitis (EAE), an inflammatory condition similar to MS, by antagonizing T...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102190

    authors： Lin B,Launder D,Bailey DY,Assifuah FK,Miller OA,Conti HR,Du J,Koffman BM

    更新日期：2020-08-01 00:00:00

  • Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13.

    abstract：BACKGROUND:Elevation of CXCL13, a key regulator of B-cell recruitment in cerebrospinal fluid (CSF) is implicated in multiple sclerosis (MS). OBJECTIVE:to evaluate if measurement of CXCL13 using a highly sensitive assay is of value in acute optic neuritis (ON) patients for the prediction of later MS. METHOD:CXCL13 was...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102281

    authors： Olesen MN,Nilsson AC,Pihl-Jensen G,Soelberg KK,Olsen DA,Brandslund I,Lillevang ST,Madsen JS,Frederiksen JL,Asgari N

    更新日期：2020-09-01 00:00:00

  • CADASIL as Multiple Sclerosis Mimic: A 48-year-old man with severe leukoencephalopathy and spinal cord involvement.

    abstract：:Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a common cause of inherited stroke in young adults. CADASIL causes extensive white matter T2 hyperintensities at brain MRI, in particular involving anterior-temporal lobes and external capsules; usually, there is no...

    journal_title：Multiple sclerosis and related disorders

    pub_type：

    doi：10.1016/j.msard.2020.102014

    authors： Motolese F,Rossi M,Gangemi E,Bersano A,Scelzo E,Di Lazzaro V,Capone F

    更新日期：2020-06-01 00:00:00

  • Spatio-temporal gait parameters change differently according to speed instructions and walking history in MS patients with different ambulatory dysfunction.

    abstract：BACKGROUND:Different walking capacity test formats are applied, but their impact on the gait pattern in persons with MS (pwMS) has not yet been investigated according to baseline velocity performance. OBJECTIVE:To assess, in pwMS with different ambulation dysfunction, the impact of speed instructions and previous walk...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2013.01.004

    authors： Feys P,Severijns D,Vantenderloo S,Knuts K,Hannes D,Gijbels D,Wens I

    更新日期：2013-07-01 00:00:00

  • Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review.

    abstract：BACKGROUND:Considering the multiple treatments approved for multiple sclerosis (MS) by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a treatment strategy for patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) can be challenging. To date, an overv...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2020.101929

    authors： Visser LA,Louapre C,Uyl-de Groot CA,Redekop WK

    更新日期：2020-01-02 00:00:00